atrasentan has been researched along with Hormone-Dependent Neoplasms in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agarwal, N; Carducci, MA; Garzotto, MG; Goldkorn, A; Higano, CS; Hussain, M; Lara, PN; Mack, PC; Moinpour, CM; Monk, JP; Quinn, DI; Tangen, CM; Thompson, IM; Twardowski, PW; Van Veldhuizen, PJ; Vogelzang, NJ | 1 |
| Taneja, SS | 1 |
| Dawson, NA | 1 |
| Carducci, M; Chin, JL; Love, W; Nelson, JB; Qian, J; Saad, F; Schulman, CC; Sleep, DJ; Steinberg, J | 1 |
2 trial(s) available for atrasentan and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Bone Neoplasms; Castration; Docetaxel; Double-Blind Method; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasms, Hormone-Dependent; Prognosis; Prostatic Neoplasms; Pyrrolidines; Survival Rate; Taxoids | 2013 |
Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alkaline Phosphatase; Atrasentan; Disease Progression; Double-Blind Method; Endothelin-1; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Placebos; Prognosis; Prostatic Neoplasms; Pyrrolidines; Treatment Outcome | 2008 |
2 other study(ies) available for atrasentan and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Re: docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Bone Neoplasms; Castration; Clinical Trials, Phase III as Topic; Docetaxel; Double-Blind Method; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasms, Hormone-Dependent; Prognosis; Prostatic Neoplasms; Pyrrolidines; Randomized Controlled Trials as Topic; Survival Rate; Taxoids | 2014 |
Targeted therapy in prostate cancer--are we our own worst enemy?
Topics: Atrasentan; Endothelin-1; Humans; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Pyrrolidines | 2008 |